Pinnacle Wealth Management LLC Takes $442,000 Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Pinnacle Wealth Management LLC acquired 14,946 shares of Hims & Hers Health, valued at approximately $442,000, indicating growing institutional interest in the company.
• Insiders, including Michael Chi and CFO Oluyemi Okupe, sold significant portions of their shares recently, reflecting a potential signal of changing confidence in the company.
• Hims & Hers Health reported an earnings miss, with a $0.17 EPS compared to the consensus estimate of $0.18, despite a revenue increase of 72.6% year-over-year.

Pinnacle Wealth Management LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,946 shares of the company's stock, valued at approximately $442,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock worth $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd increased its holdings in shares of Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after acquiring an additional 700,100 shares in the last quarter. Nuveen LLC bought a new stake in shares of Hims & Hers Health in the first quarter worth about $58,403,000. Finally, Two Sigma Investments LP increased its holdings in shares of Hims & Hers Health by 37.9% in the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock worth $47,571,000 after acquiring an additional 540,274 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 23,107 shares of the stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares of the company's stock, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,396,090 shares of company stock valued at $71,927,627. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Up 1.0%

Shares of NYSE:HIMS traded up $0.4260 during mid-day trading on Thursday, reaching $43.8060. 27,579,678 shares of the stock were exchanged, compared to its average volume of 33,761,141. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company has a market cap of $9.90 billion, a P/E ratio of 54.76, a P/E/G ratio of 2.85 and a beta of 2.08. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The stock's 50 day simple moving average is $52.18 and its 200-day simple moving average is $45.73.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm's quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Finally, Truist Financial lowered their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Reduce" and a consensus price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.